Theravance Biopharma Halves Workforce and Ends R&D After Phase 3 Failure on March 04, 2026 ampreloxetine CYPRESS study Phase 3 failure R&D shutdown Theravance Biopharma workforce reduction Yupelri +
Gossamer Bio Stock Nosedives After Late-Stage Seralutinib Failure in PAH Trial on February 24, 2026 Clinical Trials Gossamer Bio PAH Phase 3 failure PROSERA Seralutinib +
Sanofi's Tolebrutinib Faces Phase 3 Failure in PPMS and FDA Delays in nrSPMS on February 10, 2026 Deferred Multiple Sclerosis Parts per million (qualifier value) PERSEUS trial Phase 3 failure sanofi Tolebrutinib United States Food and Drug Administration +